Your session is about to expire
← Back to Search
Combination Therapy
Taltz in Combination With Enstilar for Psoriasis
Phase 4
Recruiting
Research Sponsored by Psoriasis Treatment Center of Central New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial is testing if adding Enstilar Foam to patients already using Taltz can help treat plaque psoriasis. The study focuses on patients who have been on Taltz for a significant period and have moderate psoriasis affecting 3%-8% of their body. Enstilar reduces skin symptoms, while Taltz calms the immune system.
Eligible Conditions
- Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Body Surface Area 0 or 1
Side effects data
From 2018 Phase 4 trial • 28 Patients • NCT0344178914%
upper respiratory infection
7%
hypertension
7%
compressed lumbar disc
7%
headache
7%
right ankle pain
7%
nausea
7%
dry cough
7%
bronchitis
7%
frequent muscle fasciculation right lower eyelid
7%
abrasion right shin
7%
sensation of fullness in neck
7%
generalized rash
7%
root canal
7%
persistent lower extremity edema
7%
increased joint pain generalized
7%
intertrigo
7%
right lower jaw pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Otezla Plus Vehicle Foam
Otezla Plus Enstilar Foam
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: EnstilarExperimental Treatment1 Intervention
Enstilar foam
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Calcipotriol
FDA approved
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyIndustry Sponsor
2,680 Previous Clinical Trials
3,466,359 Total Patients Enrolled
37 Trials studying Psoriasis
20,628 Patients Enrolled for Psoriasis
Psoriasis Treatment Center of Central New JerseyLead Sponsor
14 Previous Clinical Trials
417 Total Patients Enrolled
13 Trials studying Psoriasis
377 Patients Enrolled for Psoriasis